SynthesisClinical cancer research : an official journal of the American Association for Cancer Research2017
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.
Abstract readMeta-Analysis
In one paragraph
Synthesis in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Efficacy and safety of immunotherapy in anaplastic thyroid carcinoma: a systematic review and meta-analysis.International journal of surgery (London, England) · 2026Pooled it
- Anaplastic thyroid cancer: genomic landscape, molecular drivers and novel therapeutics.Nature reviews. Endocrinology · 2026Review
- Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & diseases · 2025Review
- Targeting Tumor Microenvironment Akt Signaling Represents a Potential Therapeutic Strategy for Aggressive Thyroid Cancer.International journal of molecular sciences · 2023Article
- Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Frontiers in oncology · 2023Review
- Anaplastic thyroid cancer: genome-based search for new targeted therapy options.Endocrine connections · 2022Article
- Antitumor activity of Koningic acid in thyroid cancer by inhibiting cellular glycolysis.Endocrine · 2022Article
- Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.Thyroid : official journal of the American Thyroid Association · 2021Article
- The prevalence of DNA microsatellite instability in anaplastic thyroid carcinoma - systematic review and discussion of current therapeutic options.Contemporary oncology (Poznan, Poland) · 2021Review
- Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.Molecular biology reports · 2020Review
- Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers.Endocrinology and metabolism (Seoul, Korea) · 2020Review
- BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.Cancers · 2019Review
- Identification of Targetable Lesions in Anaplastic Thyroid Cancer by Genome Profiling.Cancers · 2019Article
- Everolimus in Anaplastic Thyroid Cancer: A Case Series.Frontiers in oncology · 2019Article
- Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.Oncogenesis · 2018Article
- Article
- Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.Oncotarget · 2017Article
- Comprehensive multiregional analysis of molecular heterogeneity in bladder cancer.Scientific reports · 2017Article
- Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- In vitro Multi-targeted Anti-cancer Effects of Bavachinin in Papillary Thyroid Carcinoma Cell Line: Dual Pathway Inhibition and Cytokine Downregulation.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
William J GibsonThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Daniel T RuanDepartment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Vera A PaulsonDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Justine A BarlettaDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Glenn J HannaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Stefan KraftDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Antonio CallesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Matthew A NehsDepartment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Francis D MooreDepartment of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
Amaro Taylor-WeinerThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Jeremiah A WalaThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Travis I ZackThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Thomas C LeeDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
Fiona M FennessyDepartment of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
Erik K AlexanderDepartment of Endocrinology, Brigham and Women's Hospital, Boston, Massachusetts.
Tom ThomasDepartment of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts.
Pasi A JanneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Levi A GarrawayThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Scott L CarterThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Rameen BeroukhimThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Jochen H LorchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. eliezerm_vanallen@dfci.harvard.edu Jochen_Lorch@dfci.harvard.edu.
Eliezer M Van AllenThe Broad Institute of Harvard and MIT, Cambridge, Massachusetts. eliezerm_vanallen@dfci.harvard.edu Jochen_Lorch@dfci.harvard.edu.
Brigham and Women's Hospital · USHarvard University · US
Funding
Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MResistance to Emerging Androgen Deprivation Therapies in Prostate CancerK08CA188615 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2014 to 2017
$708kHemizygous deletion of esential genes enables a novel therqpeutic vulnerability in cancerF30CA192725 · NCI · HARVARD MEDICAL SCHOOL · PI GIBSON, WILLIAM J · 2015 to 2017
$121kNCI NIH HHS F30 CA192725NCI NIH HHS K08 CA188615NIGMS NIH HHS T32 GM007753
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug SynergismGenomicsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorExome SequencingGenetic HeterogeneityHumansMAP Kinase Kinase KinasesMutationPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins B-rafraf KinasesSignal TransductionThyroid Carcinoma, AnaplasticTOR Serine-Threonine KinasesBRAF protein, humanMAP Kinase Kinase KinasesMTOR protein, humanPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins B-rafraf KinasesTOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.